Simple supplement could prevent muscle loss from weight-loss drugs

Ketones may be the key to avoiding the potentially adverse side-effect on heart and skeletal muscle, new research shows.

251007-ozempic-and-ketones-main-16x9-3000.jpg

New research suggests a supplement of ketones may help people using semaglutide drugs like Ozempic avoid losing skeletal and heart muscle along with fat. (Photo: Getty Images)

A supplement of ketones may be the magic bullet that allows patients using weight-loss drugs to avoid the potentially adverse side-effect of a shrinking heart and skeletal muscle, according to a that “fine-tunes” the popular therapy to protect lean muscle while shedding the same amount of fat. 

“Our original study was prompted by reports showing that people taking semaglutide — the active ingredient in weight-loss drugs such as Ozempic, Wegovy and Rybelsus — lost a significant amount of skeletal muscle mass,” says , a pediatrics professor in the Faculty of Medicine & Dentistry. “We wanted to reproduce that in animal models so that we could find ways to intervene and prevent this from happening.”

In their initial studies, Dyck’s team confirmed the expected loss of skeletal muscle, which studies show can account for nearly 40 per cent of the total weight loss. But they also found an unexpected and more concerning effect: the heart was losing muscle mass as well.

Although the heart naturally shrinks with weight loss — especially if it was enlarged due to obesity — Dyck says some of the heart muscle loss appeared to be independent of the overall weight reduction. “The question is, if you have a healthy heart, what are the long-term effects of it shrinking more than it should?”

It is already known that muscle decline can lead to a host of long-term health issues including decreased immunity, increased risk of infections and poor wound healing. To address the unknowns, the team looked at a natural energy source the body produces: ketones.

Ketones are produced by the liver when the body runs low on carbohydrates, typically during fasting or when following a low-carb, or ketogenic, diet. Recent work also showed that ketones are necessary to preserve skeletal muscle mass.

For the followup study, Dyck’s team paired semaglutide with a ketone ester, a drinkable supplement that the body converts into ketones, mimicking the elevated levels of ketones in the blood.

The results in obese mice were dramatic.

"It turns out it does a fantastic job in protecting from muscle loss — skeletal muscle loss and loss of cardiac mass,” says Dyck, who is in Molecular Medicine, director of the and a member of both the and the Alberta Diabetes Institute.

Mice that received the semaglutide and ketone ester combination did not lose as much total body weight as the group receiving semaglutide alone. However, further analysis showed that this lower total weight loss was actually a positive sign.

“When we looked deeper into where that weight loss came from, the same amount of fat was lost, but the ketones prevented muscle loss,” Dyck says. “It really just fine-tunes, potentially, this therapy.”

When we looked deeper into where that weight loss came from, the same amount of fat was lost, but the ketones prevented muscle loss. It really just fine-tunes, potentially, this therapy.

Jason Dyck

Jason Dyck
(Photo: WCHRI)

The mechanism behind this protective effect appears to be centred on the body’s energy factories: mitochondria.

He explains that semaglutide appears to impair the mitochondria, which generate energy for the muscles. Without this energy, the muscle can waste away. This process happens when the body is starved and begins to break down muscle for fuel. 

“When you give animal models ketones, it protects the mitochondria from being impaired,” Dyck says. “We think the ketones are making the mitochondria more active, healthier.”

With millions of people now taking semaglutide, finding a way to make the drug safer is a major goal. Dyck’s team has secured a 伊人直播 Transformational Medical Research Grant, funded by The , to begin human trials.

“We were so far ahead comparatively, as far as hoping to one day do a clinical trial, as opposed to where we are now, which is having money in place to do one,” Dyck says. “I think it’s easy to find problems, but to actually then find solutions is fantastic.”

This research was supported in part by the , the and through the Women and Children's Health Research Institute and the Alberta Diabetes Institute.